| Members |
targetComponentId |
| N1: Unilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa (finding) |
cN1 |
| N1a: 1-3 nodes involved (finding) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in ipsilateral cervical lymph node(s) (finding) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in single regional lymph node (finding) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Only micrometastasis, none > 0.2 cm in greatest dimension (finding) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1b: 4-7 nodes involved (finding) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in bilateral, midline, or contralateral cervical or mediastinal lymph node(s) (finding) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in multiple regional lymph nodes (finding) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis to lymph node(s), any > 0.2 cm in greatest dimension (finding) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1c: >7 nodes involved (finding) |
cN1c |
| N2 category (finding) |
cN2 |
| N2: Bilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa (finding) |
cN2 |
| N2: Metastasis in 4 or more lymph nodes (finding) |
cN2 |
| N2: Metastasis in 7-15 perigastric lymph nodes (finding) |
cN2 |
| N2: Metastasis in a single ipsilat lymph node >3cm but <6cm in greatest dimension; or in multiple ipsilat lymph nodes, none >6cm in greatest dimension; or in bilat or contralat lymph nodes, none >6cm in greatest dimension (finding) |
cN2 |
| N2: Metastasis in a single lymph node, > 2 cm but <= 5 cm in greatest dimension, or multiple lymph nodes, none > 5 cm in greatest dimension (finding) |
cN2 |
| N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) (finding) |
cN2 |
| N2: Metastasis in more than one regional lymph node (finding) |
cN2 |
| N2: Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures (finding) |
cN2 |
| N2: Metastasis to unilateral internal iliac and/or inguinal lymph node(s) |
cN2 |
| N2: Metastasis with a lymph node mass >2 cm but <= 5 cm in greatest dimension, or more than 5 nodes positive, none > 5 cm; or evidence of extranodal extension of tumor (finding) |
cN2 |
| N2a: Metastasis in a single ipsilateral lymph node, > 3 cm but < 6 cm in greatest dimension (finding) |
American Joint Committee on Cancer cN2a (qualifier value) |
| N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension (finding) |
cN2b |
| N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension (finding) |
cN2c |
| N3 category (finding) |
cN3 |
| N3: Metastasis in >15 perigastric lymph nodes (finding) |
cN3 |
| N3: Metastasis in a lymph node > 5 cm in greatest dimension (finding) |
cN3 |
| N3: Metastasis in a lymph node > 6 cm in greatest dimension (finding) |
cN3 |
| N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) (finding) |
cN3 |
| N3: Metastasis in lymph node(s) (finding) |
cN3 |
| N3: Metastasis to ipsilateral internal mammary lymph node(s) (finding) |
cN3 |
| N3: Metastasis with a lymph node mass > 5 cm in greatest dimension (finding) |
cN3 |
| N3a: > 6 cm in dimension (finding) |
cN3a |
| N3b: extension to supraclavicular fossa (finding) |
American Joint Committee on Cancer cN3b (qualifier value) |
| NAD(P)H dehydrogenase (FMN) (substance) |
NAD(P)H dehydrogenase (quinone) |
| NX category (finding) |
cNX |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabothian follicles on cervix (disorder) |
Mucous retention cyst of cervix uteri (disorder) |
| Nabumetone 500mg dispersible tablet (product) |
Nabumetone 2.5 mg/mL oral solution |
| Nail flap |
Flap (substance) |
| Nairobi sheep disease serogroup |
Nairobi sheep disease virus |
| Nape of neck flap |
Flap (substance) |
| Naphazoline hydrochloride + polyvinyl alcohol + zinc sulfate 0.02%wv/0.25%wv/0.25%wv drops (product) |
Product containing only naphazoline and polyvinyl alcohol and zinc sulfate (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg m/r tablet (product) |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg prolonged-release oral tablet (product) |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 500mg m/r tablet (product) |
Product containing precisely naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 220mg/pseudoephedrine 120mg m/r tablet (product) |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 220mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 375mg gastro-resistant oral tablet (product) |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 375mg m/r tablet (product) |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 500mg gastro-resistant oral tablet (product) |
Naproxen only product in oral dose form |
| Naproxen sodium 500mg m/r tablet (product) |
Naproxen only product in oral dose form |
| Narrow open angle |
Narrow angle (finding) |
| Nasal cavity and ethmoid sinus TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Nasal diagnostic laryngoscopy |
Nasal laryngoscopy |
| Nasal flap |
Flap (substance) |
| Nasalis flap |
Flap (substance) |
| Nasolabial flap |
Flap (substance) |
| Nasopharyngoscopy: [diagnostic NEC] or [NEC] |
Nasopharyngoscopy |
| Nasopharynx TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Nausea |
nausées |
| Near complete invasion of mesorectum by tumor (finding) |
Mesorectal specimen nearly completely intact (finding) |
| Neck of other metacarpal |
Neck of metacarpal bone structure (body structure) |
| Neer 2 part fracture |
Neer two-part fracture |
| Neer 3 part fracture |
Neer three-part fracture |
| Neer 4 part fracture |
Neer four-part fracture |
| Negroid nose (finding) |
Nose finding |
| Neisseria meningitidis group Z' |
Neisseria meningitidis de groupe Z |
| Neomycin sulfate 0.5% conventional release eye drops (product) |
Product containing only neomycin in ocular dose form (medicinal product form) |
| Neomycin sulfate 0.5% single-use eye drops (product) |
Product containing only neomycin in ocular dose form (medicinal product form) |
| Neomycin+hydrocortisone 0.5%/1.5% ear drops (product) |
Hydrocortisone 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL ear solution |
| Neonatal calf diarrhea coronavirus |
coronavirus bovin |
| Neonatal candida infection |
Neonatal candidiasis (disorder) |
| Neonatal candidiasis of mouth (disorder) |
Neonatal candidiasis (disorder) |
| Neonatal intestinal perforation co-occurrent and due to congenital intestinal stenosis (disorder) |
Neonatal perforation of intestine due to congenital stenosis of intestine |
| Neonatal monilia infection (disorder) |
Neonatal candidiasis (disorder) |
| Neonatal thrombocytopenia due to isoimmunization |
thrombocytopénie néonatale transitoire |
| Neophema bourkii |
Neopsephotus bourkii (organism) |
| néoplasme selon la localisation corporelle |
maladie néoplasique |
| Neoplasm of perivascular myoid type - category (morphologic abnormality) |
Perivascular myoid neoplasm (morphologic abnormality) |
| Neoplastic process |
Neoplasm |
| Neotran |
Bis-(p-chlorophenoxy) methane |
| Neovascularization of iris AND/OR ciliary body (disorder) |
Disorder of uveal tract |
| Nephrogenic diabetes insipidus |
Nephrogenic diabetes insipidus |
| Nephrolithiasis (disorder) |
Kidney stone |
| Nerve bundle |
Central nervous system tract structure |
| Nerve conduction deafness |
Neural hearing loss |
| Nerve sheath tumor, no ICD-O subtype |
Benign nerve sheath tumor |
| Nesochen sandvicensis (organism) |
Branta sandvicensis (organism) |
| Nettle rash |
Urticaria |
| Neuralgia (disorder) |
névralgie (constatation) |
| Neurinomatosis |
Melanotic schwannoma |
| Neurocutaneous melanosis sequence |
Neurocutaneous melanosis |
| Neuroectodermal endocrine syndrome (disorder) |
Woodhouse Sakati syndrome |
| Neurofibramatosis 3 |
Schwannomatosis |
| Neurofibroma |
Benign neurofibroma |
| Neurofibromatosis, type 3 |
Schwannomatosis |
| Neuroleptic malignant syndrome |
Neuroleptic malignant syndrome |
| Neurologic myelopathy-retired |
Spinal cord disorder (disorder) |
| Neurological disorder caused by ingestible alcohol (disorder) |
Neurological disorder caused by ethanol (disorder) |
| Neurological status not worse than preoperative baseline (finding) |
état neurologique stable ou amélioré par rapport à l'état préopératoire |
FHIR